Retatrutide Cut Large Triglyceride Particles 84%—But Read This First
Retatrutide is best known for weight loss, but a new post hoc analysis of two phase 2 trials looked at what it did to the blood. Large triglyceride-rich lipoprotein particles fell by up to 84.4% in adults with type 2 diabetes, and ApoB dropped by roughly 21–24%. In the trial without diabetes, hsCRP fell 54.8% and IL-6 fell 29.6%, but those changes were not significant in the diabetes trial. The abstract reports no Lp(a) results and no per-dose breakdown. This is an unapproved prescription-class drug, not a supplement, and these are biomarkers, not proof of fewer heart attacks.
Akkermansia Missed Its Main Goal—Except in People Who Lacked It
A pasteurized gut bacterium often pitched as a "natural GLP-1 booster" just faced a 142-person, double-blind trial, and it missed its primary insulin-sensitivity endpoint. But exploratory analyses showed a post-glucose GLP-1 rise, and people with low baseline Akkermansia saw better insulin sensitivity and less trunk fat. Those subgroup results are hypothesis-generating, sit close to the significance threshold, and come from a study with heavy industry involvement. Here is what the data show, what they don't, and who might care.